Phase2Phase offers to assist not only with CMC services. In validated investment cases we are open to share risks in terms of funding. Our investments are made separately or as a part of an investor network.
Our current portfolio companies are:
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate that provides a novel mechanism of action and is therefore assumed to have less adverse effects than current treatments in use.
Athera Biotechnologies AB is a dynamic company with a vision to address the need for improved treatment of vascular disease patients and is now pursuing clinical development with its anti-inflammatory antibody.